TEMPO
Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017.
“2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.”
Highlights for 2017 include:
- Revenue grew 38% year-over-year to US$17.9 million
- Almost 2,000 new customers were acquired
- Launched our new cloud infrastructure
- Expanded product footprint beyond the Atlassian environment with Tempo for Slack
- North American operations continued to grow
- More than 120 partners worldwide
- Celebrated our 10-year anniversary
Revenue improved by 38% year-over-year
Tempo’s annual earnings increased by 38% year-over-year to US$17.9 million, fueled by double-digit growth across all our deployment options and products. The Company’s client base is highly diversified across company size and industry sector, helping to stabilize Tempo’s revenue and protect against sector downturns.
New cloud platform
In 2017, with the migration of more than 7,000 customers, Tempo moved to hosting its own cloud environment. Which drew to close the major transition and investment that this 18-month project required.
The company has not only built new products and infrastructure to solidify the foundation of our cloud vision, but has also redesigned and established new processes as well as ways of working, transforming ourselves from software supplier to a world-class services company. Customers will benefit from improved performance and reduced latency on the Amazon Web Services Platform, and can expect to see more frequent product releases in response to emerging requirements.
Tempo for Slack
Tempo for Slack integrates its time management solution tightly within the chat platform allowing users expedited productivity and real-time reporting. Slack customers using Jira will be able to use Tempo to seamlessly track their time, receive notifications and reminders, as well as alerts to approve timesheets all within the same environment.
North America operation continues to expand
This year Tempo added 17 employees to our Montreal office, while maintaining a strong team at its headquarters in Iceland, bringing the total number of employees close to 100.
10-year anniversary and almost 2,000 new customers acquired
Tempo marked its 10-year anniversary and surpassed 10,000 customers in Q2 2017. This year saw further growth to almost 12,000 customers, since its launch almost a decade ago. Significant new clients including: Bank of Singapore, Airbus Defence and Space, Verizon, NBC Universal, Rolex and many others.
Over 120 partners worldwide
Collaborative growth is key to the strength of Tempo, and in 2017 our Atlassian Expert Partner network grew to a total of over 120 Partners worldwide. Tempo is looking forward to fostering and strengthening partnerships with both existing and potential partners as well as customers in 2018.
Other highlights:
- Launched Tempo for Chrome extension
- Launched a more powerful and custom time report for Tempo Cloud
- Donated over $105,000 to the non-profit Room to Read. Amount calculated from all proceeds of 10-user starter license sales. Room to Read seeks to improve literacy and gender equality in education in the developing world
- Renewed our participation in the Pledge 1% corporate philanthropy movement, founded by Atlassian, Salesforce, and Rally.
###
About Tempo
Tempo develops sophisticated software solutions that help make work easier and more efficient for software, IT services and core business teams. Tempo has over 11,000 customers worldwide, ranging from small startups to the largest global enterprises including Amazon, BMW, Pfizer, HomeAway, PayPal, Hulu, Dell, and Disney.
To learn more about Tempo, visit www.tempo.io .
Additional Resources
Follow the Tempo blog: http://blog.tempo.io
Follow us on Twitter: http://twitter.com/tempohq
Become a fan on Facebook: http://facebook.com/tempohq
Follow us on LinkedIn: https://www.linkedin.com/company/TempoHQ
View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005219/en/
Contact:
Media Contact:
Tempo
Agust Einarsson
CEO
ae@tempo.io
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom